Street Calls of the Week
Investing.com - JPMorgan has reiterated an Overweight rating and EUR730.00 price target on argenx SE (BR:ARGX) (NASDAQ:ARGX), a $43 billion market cap biotech company with remarkable 88% revenue growth, following positive clinical trial results. According to InvestingPro data, the company maintains strong financial health with a "GREAT" overall score, supported by robust cash flows and solid balance sheet metrics.
The company announced positive headline results from the ADAPT SERON trial, which tested Vyvgart in generalised Myasthenia Gravis (gMG) patients who tested negative for AChR antibodies.
The trial demonstrated that Vyvgart generated a statistically significant and clinically meaningful improvement in the MG-ADL total score, showing improvement in disease activity across all three subtypes of patients enrolled.
Safety results were consistent with previous trials of Vyvgart in gMG, according to the company’s announcement.
JPMorgan noted that the positive results from the ADAPT SERON trial will broaden the label for Vyvgart in gMG, further enhancing the competitive profile of the product.
In other recent news, Argenx reported robust earnings for Q2 2025, significantly exceeding market expectations. The company announced earnings per share of $6.32, more than double the anticipated $3.06, resulting in a 106.54% surprise. Additionally, revenue reached $1.74 billion, surpassing the forecasted $876.3 million by 98.56%. In terms of clinical advancements, Argenx’s Vyvgart treatment has shown positive results in a Phase 3 trial for seronegative myasthenia gravis, achieving statistical significance versus a placebo. This development has led Oppenheimer to reiterate its Outperform rating with a price target of $778.00. RBC Capital also reiterated its Outperform rating, setting a price target of $850.00, citing Vyvgart’s meaningful benefits across all antibody status subtypes. RBC Capital further initiated coverage on Argenx with an Outperform rating due to the company’s significant growth since 2022. These recent developments highlight Argenx’s advancements in both financial performance and clinical trials.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.